alfuzosin vs nirmatrelvir/ritonavir
Side-by-side comparison of alfuzosin and nirmatrelvir/ritonavir. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
major Known Drug Interaction
Table 2: Established and Other Potentially Significant Drug Interactions Drug Class Drugs within Class Effect on Concentration Clinical Comments Alpha 1- adrenoreceptor antagonist alfuzosin ↑ alfuzosin Co-administration contraindicated due to potential hypotension [see Contraindications (4) ] .
Recommendation: You must not take these two drugs at the same time. Ask your doctor for a different treatment option.
Uroxatral
Paxlovid
Alfuzosin is a medicine that helps men with enlarged prostate glands. It relaxes the muscles in the prostate and bladder, making it easier to urinate.
Paxlovid is a medicine used to treat mild to moderate COVID-19 in adults. It helps prevent severe illness, hospitalization, or death in people at high risk.
This medicine treats the symptoms of benign prostatic hyperplasia (BPH), also known as an enlarged prostate. BPH can cause problems with urination, such as difficulty starting or stopping, frequent urination, and feeling like you can't empty your bladder. Alfuzosin helps to improve these symptoms.
Paxlovid treats mild to moderate COVID-19 in adults. You must be at high risk of your illness becoming severe. This includes needing to go to the hospital or possibly dying from COVID-19. Paxlovid is not for preventing COVID-19 before or after exposure.
Alfuzosin belongs to a class of drugs called alpha-1 blockers. It works by relaxing the muscles in the prostate and bladder neck. This relaxation allows urine to flow more freely, relieving the symptoms of BPH.
Paxlovid contains two medicines, nirmatrelvir and ritonavir. Nirmatrelvir stops the virus from multiplying in your body. Ritonavir helps nirmatrelvir stay in your body longer so it can work better.
- • Dizziness
- • Upper respiratory tract infection
- • Headache
- • Fatigue
- • Change in taste
- • Diarrhea
- Difficulty breathing 89
- The medicine is interacting with another medicine 87
- Tiredness 87
- Sudden damage to the kidneys 79
- Feeling lightheaded or unsteady 74
- COVID-19 22,774
- COVID-19 coming back 20,089
- Change in taste 7,316
- Diarrhea 4,003
- Feeling sick to your stomach 2,620
Alfuzosin can cause your blood pressure to drop suddenly when you stand up, leading to dizziness or fainting. Be careful when standing up quickly, especially when you first start taking this medicine. If you have chest pain (angina), tell your doctor immediately. This medicine may also affect your heart rhythm. Tell your doctor if you have a history of heart problems.
Paxlovid can interact with many other medicines, causing serious or life-threatening problems. Before taking Paxlovid, tell your doctor about all the medicines you take. Your doctor may need to adjust the dose of your other medicines or monitor you more closely.
This medicine is only for men and is not intended for use in women. It is not known if alfuzosin can harm an unborn baby or pass into breast milk.
There is not enough information about nirmatrelvir's safety during pregnancy. Studies on ritonavir in pregnant women have not shown an increased risk of birth defects. Talk to your doctor about the risks and benefits of taking Paxlovid if you are pregnant or breastfeeding.
How to Read This alfuzosin vs nirmatrelvir/ritonavir Comparison
alfuzosin is classified in the Alpha-1 Blocker (BPH) drug class, while nirmatrelvir/ritonavir sits within the Antiviral (Protease Inhibitor Combination) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, alfuzosin has 416 submissions while nirmatrelvir/ritonavir has 56,802. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known major interaction flagged in FDA labeling, attributed to nirmatrelvir/ritonavir causes alfuzosin to build up in your body by slowing its removal. this can lead to a dangerous drop in your blood pressure.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between alfuzosin and nirmatrelvir/ritonavir - always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.